Court Extends Deadline for Claims Vs. Bristol-Myers
The U.S. District Court for the District of Columbia has given cancer patients treated with Taxol (paclitaxel) another three months to file claims against Bristol-Myers Squibb for delaying generic competition by...To view the full article, register now.
Already a subscriber? Click here to view full article